FDA advisory panel votes 8 to 6 to back compounding of BPC-157, HIMS jumps 13%
The recommendation to add BPC-157 to the 503A bulks list isn't final; the FDA still decides. Six other peptides, including TB-500 and Semax, are under review.
Recap by typeshit. Full story at Stocktwits.